Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

But Where is My Doctor? The Increasing and Relentless Fragmentation of Oncology Care.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

The role of occipital artery resection in the surgical treatment of occipital migraine headaches.

Plastic and reconstructive surgery·2013
Same author

Oncodoxes.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2012
Same author

Small bowel obstruction after hysterectomy to treat benign disease.

Journal of minimally invasive gynecology·2012
Same author

Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer.

Clinical breast cancer·2011
Same author

Reanalysis of a randomized trial of 3 techniques of anterior colporrhaphy using clinically relevant definitions of success.

American journal of obstetrics and gynecology·2011
Same journal

Incidence of Induction Toxicities in Childhood Acute Lymphoblastic Leukaemia in Ghana.

Advances in hematology·2026
Same journal

Vaccination and Antiviral Combination Improves Resolution Time of COVID-19 Infection in Treated Multiple Myeloma: A Retrospective Study.

Advances in hematology·2026
Same journal

The Natural Coagulation Inhibitors, Inflammation, and Thrombotic Risk in Sickle Cell Patients in Cameroon: An Analytical Cross-Sectional Study.

Advances in hematology·2026
Same journal

Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community Settings.

Advances in hematology·2026
Same journal

Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns.

Advances in hematology·2025
Same journal

Positive Indirect Antiglobulin Test in Adult Patients With Primary Warm Autoimmune Hemolytic Anemia: Clinical Significance and Prognostic Effect on Response to Corticosteroids.

Advances in hematology·2025
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

Drug-induced hematologic syndromes.

David M Mintzer1, Shira N Billet, Lauren Chmielewski

  • 1Section of Hematology and Medical Oncology, Pennsylvania Hospital, Philadelphia, PA 19106, USA.

Advances in Hematology
|December 5, 2009
PubMed
Summary
This summary is machine-generated.

Medications can cause a wide array of blood disorders, impacting all blood cell types and clotting. Healthcare providers must recognize these drug-induced hematologic syndromes, including those from newer biologic agents.

Related Experiment Videos

Last Updated: Jun 18, 2026

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells
11:06

Identifying DNA Mutations in Purified Hematopoietic Stem/Progenitor Cells

Published on: February 24, 2014

Area of Science:

  • Hematology
  • Pharmacology
  • Internal Medicine

Background:

  • Drugs are known to induce a vast spectrum of hematologic disorders.
  • These effects can impact white blood cells, red blood cells, platelets, and the coagulation system.
  • Emerging drug classes, including biologics, present novel hematologic toxicities.

Purpose of the Study:

  • To highlight the extensive range of drug-induced hematologic syndromes.
  • To identify newer medications and associated hematologic complications.
  • To underscore the importance of physician awareness regarding iatrogenic hematologic issues.

Main Methods:

  • A comprehensive review of the Medline literature on drug-induced hematologic syndromes.
  • Focus on identifying diverse syndromes beyond individual drug or cytopenia reports.

Main Results:

  • Drug-induced syndromes encompass hemolytic anemias, methemoglobinemia, red cell aplasia, sideroblastic anemia, megaloblastic anemia, polycythemia, aplastic anemia, leukocytosis, neutropenia, eosinophilia, immune thrombocytopenia, microangiopathic syndromes, hypercoagulability, hypoprothrombinemia, circulating anticoagulants, myelodysplasia, and acute leukemia.
  • Newer drugs, particularly biologics, are associated with unique hematologic side effects.
  • Multiple mechanisms underlie these drug-induced hematologic toxicities.

Conclusions:

  • Medications can induce a broad array of hematologic syndromes through various mechanisms.
  • Physicians must remain vigilant for potential drug-induced hematologic complications.
  • Awareness of both classic and novel drug-induced hematologic syndromes is crucial for patient care.